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Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) is a condition, in which triglyceride accumulates in hepatic cells without
a history of alcohol consumption and is strongly associated with insulin resistance, obesity, diabetes mellitus, hypertension and
dyslipidemia. The potential role of vitamin D in the pathogenesis of NAFLD has been reported.
Objectives: The aim of this study was to determine the optimal vitamin D levels for prevention of NAFLD.
Methods: In a cross-sectional study, 2,160 cases who referred to a university-affiliated health center were randomly selected and
their demographic information, anthropometric and metabolic indices and also vitamin D levels were collected. Fatty liver was
assessed by fatty liver index (FLI) and confirmed by FibroScan using controlled attenuation parameter (CAP). Based on the NAFLD
score, the subjects were divided into two groups and the vitamin D cutoff point was calculated by ROC curve.
Results: Based on the results, 745 patients (34.5%) had different degrees of fatty liver. Significant differences in the stiffness of liver
tissue were observed between vitamin D categories (285.10± 30.56 for severe, 251.82± 42.63 for moderate and 201.02± 36.08for
mild deficiency). According to the multivariate analysis, age, fasting insulin and vitamin D levels were found as the most significant
factors in NAFLD pathogenesis. Vitamin D cutoff point was obtained 18 nmol/L in women and 21 nmol/L in men.
Conclusions: The results indicated a significant association between vitamin D level and NAFLD score. Accordingly, increasing the
public awareness to maintain a proper level of vitamin D may be a preventative strategy against NAFLD.
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1. Background
Nonalcoholic fatty liver disease (NAFLD) is character-
ized by hepatic lipid accumulation in hepatocytes without
a history of alcohol consumption (1). It is the most com-
mon liver disease worldwide with the prevalence of 25-35%
in different populations (2). The total prevalence of NAFLD
and also the prevalence of mild, moderate and severe fatty
liver disease were estimated 33.9% (95% CI: 26.4% - 41.5%),
26.7% (95% CI: 21.7% - 31.7%), 7.6% (95% CI: 5.7% - 9.4%), and
0.5% (95% CI: 0.1% - 0.9%), respectively (3, 4). People with
the age range of 40 - 60 years or in some cases younger, are
more likely to develop NAFLD.
Epidemiological studies have demonstrated that re-
gardless of the interferer factors, such as obesity and in-
sulin resistance (IR), there is an association between hy-
povitaminosis D and the presence of NAFLD and steato-
hepatitis (NASH) (5-7). Furthermore, anti-fibrotic, anti-
inflammatory and insulin-sensitizing effects of vitamin D
on hepatocytes have been confirmed by several studies (8).
Accordingly, it seems that vitamin D possibly plays a criti-
cal important role in the pathogenesis of NAFLD (1). It has
been shown that the reduced level of 25-hydroxy vitamin D
(25(OH)D) is associated with the progression of NAFLD (2,
9-11). In some studies, however, no association was found
between vitamin D levels in patients with non-cirrhotic liv-
ers and those with liver cirrhosis or also between vitamin
D levels in patients with NAFLD and healthy individuals
(12). Nevertheless, previous studies have faced some limi-
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tations, including a small sample size and no assessment
for major interferer factors, such as obesity, insulin resis-
tance, physical activity and energy intake. A recently pub-
lished study in Asia shows that the association between vi-
tamin D level and NAFLD is varied among the Asian and
non-Asian populations (13), which can be due to the differ-
ences in the vitamin D receptor alleles among the Asian
and Western societies. The results of a recently published
systematic review on 5,000 patients with NAFLD and 8,000
healthy individuals (control) demonstrated that there is
a vitamin D deficiency in NAFLD patients, indicating that
this vitamin could be a part of the pathogenesis of NAFLD.
NAFLD patients are 26% more likely to have vitamin D defi-
ciency. This relationship is more obvious by comparing the
Western and Eastern societies (14). The increased number
of new cases of NAFLD in Iran indicates the importance of
raising public awareness and also developing appropriate
preventive and therapeutic strategies for management of
NAFLD.
2. Objectives
Due to the high prevalence of NAFLD, inconsistent re-
sults of different relevant studies and also the effects of en-
vironmental and nutritional factors on the pathogenesis
of the disease, this study aimed at evaluating the preva-
lence of vitamin D deficiency in patients with NAFLD and
healthy individuals.
3. Methods
This study is a part of a larger project to investigate
the factors affecting the development of nonalcoholic fatty
liver in an Iranian sample population (Tehran). For this
purpose, the information of 2,160 people who referred to a
university affiliated nutrition consolidation center follow-
ing a recall from the early April 2016 to the late Septem-
ber 2017 (a period of little over a year) was randomly se-
lected and investigated. The inclusion criteria included al-
cohol consumption less than 30 g/d for men and 20 g/d for
women and the subjects’ willingness to participate in the
study (15). Exclusion criteria also included those with di-
abetes, cancer, hypothyroidism or other disorders or tak-
ing medications that influence the metabolic status of the
body. In addition, those who changed their diet over the
last six months and consumed the supplements contain-
ing vitamin D, were also excluded.
The study protocol was in accordance with the Helsinki
Declaration and confirmed by the Ethics Committee of
Fasa University of Medical Sciences (approval code:
IR.FUMS.REC.1396.267). The participants were informed
about the research objectives and the written informed
consent was obtained from the subjects before starting
the survey. The study was supported by the Fasa University
of Medical Sciences (grant No.: 96050).
The demographic characteristics, including age, gen-
der and woman’s menopausal status were asked from the
participants. The weight and height of the subjects were
measured and recorded by a trained researcher using a
stadiometer accurate to 0.1 cm and the Seca 767 digital
scale (± 0.1 kg; Seca; Japan), respectively. Body mass index
(BMI) was also calculated as weight in kilograms divided by
height in meters squared.
Blood pressure was measured 15 minutes after rest in
the sitting position two times within a 15-minute interval
from the right arm of the subjects. The mean value of these
two measurements was considered as the final blood pres-
sure.
The subjects’ food intake data over the past year were
collected by the semi-quantitative food frequency ques-
tionnaire (FFQ). FFQ includes a list of 168 food items and
also portion size information as standardized portions.
The subjects were asked if they had eaten a particular food
item (standardized portions) within the last year. The col-
lected values for each food were converted into daily in-
take (g/day) using a household scales guidebook, based on
which the energy intake of the subjects was calculated.
To measure the levels of serum lipids, blood sugar and
insulin, 10 cc venous blood sample was drawn after 12
hours of fasting. The blood sample was then transferred
to the laboratory under appropriate conditions to perform
biochemical tests. High-density lipoprotein (HDL), triglyc-
eride (TG) and total cholesterol levels were measured using
enzymatic method by commercially available kits (Pars Az-
moon Laboratories, Iran). In addition, the Friedewald for-
mula (FF) was employed to calculate low-density lipopro-
tein (LDL) level (16). Eventually, the total values of serum
lipids were reported as mg/dl. Using 75 g glucose, we mea-
sured 2-hour plasma glucose and insulin.
Homeostatic model assessment (HOMA) is used for as-
sessing IR and β-cell function (7).
25(OH)D was measured through the enzyme-linked
immunosorbent assay (ELISA) kits (item No.: 501050; Cay-
man Chemical Co., USA). Its levels were then classified
based on the results of Lips study (17). The values below
12.5 nmol/L, between 12.5 and 25 nmol/L, between 25 and 50
nmol/L and higher than 50 nmol/L were considered as se-
vere vitamin D deficiency, moderate vitamin D deficiency,
mild vitamin D deficiency and vitamin D replete, respec-
tively.
Fatty liver index (FLI) was used to measure liver steato-
sis (18). The participants were assigned into three groups
based on the FLI values: FLI < 30 was defined as not hav-
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ing NAFLD, FLI≥ 60 was defined as having NAFLD and pa-
tients with FLI of 30 - 59 were defined as having intermedi-
ate FLI. The results were then confirmed (Pearson correla-
tion = 0.698, P value < 0.001) by an Gastroenterologist with
the extent of stiffness of liver mass using controlled attenu-
ation parameter (CAP) measured with FibroScan XL probe,
which is a more reliable diagnostic tool for the obese peo-
ple and those who have high fat levels (19-21).
FLI = [e0.953 × loge (TG) + 0.139 × BMI + 0.718 × loge
(GGT) + 0.053× waist circumference - 15.745)]/[1 + e0.953 ×
loge (TG) + 0.139×BMI + 0.718× loge (GGT) + 0.053×waist
circumference - 15.745]× 100, with triglycerides measured
in mmol/l, GGT in U/L, and waist circumference in cm.
3.1. Statistical Methods
The data were considered to be normally distributed.
Based on the normal distribution results, for descriptive
statistics, the mean± SD and No. (%) were used for quan-
titative and qualitative variables, respectively. Univariate
analysis was performed using the chi-Square test or in-
dependent samples t-test. To assess the simultaneous ef-
fect of variables on NAFLD, logistic regression was imple-
mented and the linear regression was also applied to find a
model based on effective factors on NAFLD. For logistic re-
gression, we proceeded in two steps; initially, only the vi-
tamin D variable was entered. In the next step, all related
variables were analyzed by Forward: conditional method
and the amount of variance explained in each step was in-
vestigated. Two model was selected. The first model with
three variables and the second model with four variables
explained 82.5% and 82.5% of the variance, respectively. Ac-
cordingly, the second model with three variables was se-
lected as the optimal model. To assess the model accu-
racy, the probability of NAFLD for each participant was es-
timated using the proposed model and the optimal cut-off
point was obtained using the receiver operating character-
istic (ROC) curve analysis. All the statistical analyses were
performed by MedCalc 14.0 (Medcalc software, Ostend, Bel-
gium) or SPSS 20.0 (IBM Co., Armonk, NY, USA).
4. Results
2,160 subjects participated in the study, of whom 745
subjects (34.5%) had NAFLD, whereas 1,415 subjects (65.5%)
were healthy. The demographic characteristics of the sub-
jects based on the groups are shown in Table 1. Almost
all studied variables, except for the gender and smoking
showed a significant difference between two groups. The
odds ratio values in the univariate model were calculated
for all factors associated with fatty liver. It can be stated
that all variables were found to increase the risk of NAFLD.
In the studied subjects, no participant had adequate
levels of vitamin D and 845, 1,055, and 260 subjects had
mild, moderate, and severe vitamin D deficiency, respec-
tively.
Using regression model, we tried to determine the role
of vitamin D in the development of NAFLD. For this pur-
pose, different variables (age, sex, woman’s menopausal
status, BMI, waist circumference, waist-to-hip ratio (WHR),
waist-to-height ratio (WHtR), physical activity, fasting
blood sugar (FBS), 2 hours blood glucose, fasting insulin,
2 hours insulin, HOMA-IR, LDL, HDL, total cholesterol, TG,
systolic blood pressure, diastolic blood pressure, alanine
aminotransferase (ALT), aspartate aminotransferase (AST),
gamma-glutamyl transferase (GGT), total energy intake
and vitamin D) were introduced into a stepwise model and
the level of inferential variance was examined by the mod-
els. Three regression models were chosen. In the first
model, only vitamin D was introduced. In this model, by
considering the mild vitamin D deficiency as the reference,
the risk of NAFLD for the groups with moderate and se-
vere vitamin D deficiencies obtained about 5 and 13, respec-
tively. In the second model, in addition to vitamin D, age
and fasting insulin variables were also introduced and the
model explained about 82.5% of the variance. Those with
moderate and severe vitamin D deficiencies were 4.2 and
2.4 times more at risk for developing NAFLD, respectively.
In the third model, ALT was added and the model explained
82.5% of the variance. It was found that those with moder-
ate and severe vitamin D deficiencies were 3.6 and 2.1 times
more at risk for developing NAFLD compared to the mild
deficiency (Table 2).
Table 3 shows the cut-off point for vitamin D in men and
women, vitamin D levels lower than 18 (nmol/L) for women
and 21 (nmol/L) for men significantly increase the risk of
NAFLD (Figure 1).
5. Discussion
The results showed an association between 25(OH)D
and NAFLD independent variables, including anthropo-
metric indicators, energy intake, physical activity and bio-
chemical indices. Furthermore, the developed models for
predicting NAFLD based on the various variables suggested
a significant correlation between NAFLD and age, fasting
insulin and the level of 25(OH)D. In addition, our study in-
dicated that 20 - 25 nmol/L of 25(OH)D is an acceptable level
to prevent NAFLD in men and women.
A recently published systematic review including 45
cross-sectional studies, revealed that 29 studies (64.4%)
reported an inverse relationship between vitamin D lev-
els and NAFLD, whereas 16 studies (35.6%) were unable to
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Table 1. Demographic and Basic Information of the Participants in Healthy and Patient Groupsa
Healthy People (N = 1415) NAFLD Patient (N = 745) P Value OR 95% CI
Lower Upper
Age, y 35± 9 49± 8 < 0.001 1.19 1.173 1.207
Weight, kg 80.88± 12.27 96.16± 11.50 < 0.001 1.103 1.093 1.113
BMI, kg/m2 25.43± 4.10 30.95± 3.49 < 0.001 1.413 1.371 1.457
Waist circumference, cm 96.49± 16.04 118.10± 12.77 < 0.001 1.097 1.088 1.106
Physical activity, MET/24h 24.9± 5.0 18.3± 4.5 < 0.001 0.762 0.744 0.781
Energy, kcal 2405.49± 413.73 2664.98± 460.11 < 0.001 1.001 1.001 1.002
FBS, mg/dL 99.39± 13.53 118.29± 13.15 < 0.001 1.102 1.092 1.111
Fast Insulin,µU/mL 8.16± 3.78 14.17± 3.39 < 0.001 1.496 1.446 1.547
Two hour glucose, mg/dL 115.22± 19.05 130.51± 20.18 < 0.001 1.039 1.034 1.044
Two hour insulin,µU/mL 40.28± 12.44 54.67± 12.40 < 0.001 1.093 1.084 1.103
HOMA-IR 0.92± 0.24 1.17± 0.23 < 0.001 70.605 45.294 110.060
HOMA-B 68.18± 15.90 79.28± 18.02 < 0.001 1.040 1.034 1.046
LDL, mg/dL 93.72± 15.56 113.71± 16.61 < 0.001 1.077 1.069 1.085
HDL, mg/dL 48.18± 7.95 38.88± 7.08 < 0.001 0.858 0.846 0.871
TG, mg/dL 186.57± 26.15 214.28± 25.03 < 0.001 1.041 1.037 1.045
Total cholesterol, mg/dL 176.01± 17.11 195.40± 16.18 < 0.001 1.072 1.064 1.079
Systolic blood pressure, mmHg 12.47± 1.63 13.09± 1.66 < 0.001 1.256 1.188 1.327
Diastolic blood pressure, mmHg 8.04± 1.02 8.84± 0.96 < 0.001 2.205 1.997 2.435
ALT, IU/L 39.77± 13.65 59.38± 13.50 < 0.001 1.104 1.094 1.113
AST, IU/L 32.40± 13.87 49.51± 12.62 < 0.001 1.094 1.085 1.103
GGT, IU/L 23.64± 10.14 36.86± 12.98 < 0.001 1.102 1.092 1.113
Vitamin D, nmol/L 26.77± 8.26 15.84± 5.50 < 0.001 0.804 0.789 0.820
Gender 0.001 0.741 0.621 0.886
Female 656 (62.1) 401 (37.9)
Smoking 0.914 1.013 0.799 1.284
Yes 240 (17) 125 (16.8)
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; FBS, fasting blood sugar; GGT, gamma-glutamyl transferase; HDL,
high-density lipoprotein; HOMA-IR, homeostasis model of insulin resistance; HOMA-β, Homeostatic model assessment of β cell function; LDL, low-density lipoprotein;
TG, Triglyceride.
aValues are expressed as mean± SD or No. (%).
demonstrate a correlation between these two (22). The op-
timal threshold for vitamin D in chronic liver disease has
reported 10 to 32 ng/mL in (22), which is equal to 24 - 80
nmol/L.
NAFLD is a multifaceted condition, affecting various as-
pects of the patient’s life, in which several factors, includ-
ing genetics (23), lifestyle (24), diet (25) and anthropomet-
ric factors (26) are involved. Vitamin D has recently been
attracted attention as NAFLD risk factor as numerous stud-
ies have investigated the association between the levels of
serum vitamin D and the risk of NAFLD. Consistent with
our results, almost all studies have found that vitamin D
deficiency is correlated with the increased risk of NAFLD
(2, 6). Bril et al. study on the relationship between NAFLD
and serum vitamin D level showed no correlation between
these variables, which is not consistent with our results
(27). However, since the majority of the relevant studies
have not been able to study all affecting variables and mod-
ify them, no reliable conclusions have yet been provided.
On the other hand, several studies evaluated only a lim-
ited number of factors, including ALT to diagnose NAFLD,
which reduces the accuracy of their studies.
Various mechanisms have been proposed for the rela-
tionship between vitamin D and the incidence of NAFLD.
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Table 2. Relationship Between Vitamin D Levels and the State of Disease
Model 1aOR (95% CI) Model 2bOR (95% CI) Model 3cOR (95% CI)
Age, y - 1.144 (1.114 - 1.175) 1.079 (1.058 - 1.099)
Fasting insulin,µU/mL - 1.284 (1.189 - 1.386) 1.183 (1.131 - 1.238)
ALT 1.029 (1.018 - 1.040)
Vitamin D mild deficiency Ref Ref Ref
Vitamin D moderate deficiency 5.858 (4.144 - 8.281) 4.257 (2.498 - 7.255) 3.616 (2.104 - 6.214)
Vitamin D severe deficiency 13.914 (10.149 - 19.075) 2.416 (1.669 - 3.497) 2.148 (1.476 - 3.126)
aLogistic regression with only one predictor variable.
bMultivariate logistic regression with 3 variables that explains 82.5% of model variance.
cMultivariate logistic regression with stepwise method that excluded Sex, Menopause, Waist cicumference, Waist to hip ratio, Waist to height ratio, physical activity,
FBS, 2 hours Glucose, HOMA-IR, LDL, HDL, total cholestrol, systolic blood pressure, diastolic blood pressure, ALT, AST, GGT and total energy intake that explains 82.5% of
models variance.
Table 3. Receiver Operating Characteristic Curve Analysis for Defining the Ideal Vitamin D Cut-Off Point Based on Nonalcoholic Fatty Liver Diseasea
Cut Point Sensitivity Specificity AUC PPV NPV PLR NLR
Female 18.25 76.06 80.64 86.5 66.93 86.73 3.90 0.30
Male 21.5 81.40 77.73 85.8 65.31 89.02 3.66 0.24
Abbreviations: AUC, Area under the curve; PPV, Positive predictive value; NPV, Negative predictive value; PLR, Positive likelihood ratio; NLR, Negative likelihood ratio.
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Figure 1. ROC curves for NAFLD using vitamin D. (Left) ROC for males (right) ROC for females.
Vitamin D plays its significant intracellular role through
bonding with vitamin D receptor (VDR). It has been shown
that VDR influences the expression of over 200 genes in-
volved in metabolism, of which inflammation (28) or cel-
lular differentiation (29) should be considered as inflam-
mation plays a significant role in developing NAFLD (30).
VDR is also expressed by macrophages. In animal studies,
it has been shown that the active form of vitamin D is able
to enhance stability of mRNA of the IκB-α (inhibitor of NF-
κB) and reduce its phosphorylation, indicating the anti-
inflammatory effect of vitamin D in macrophages (31).
The results of genome-wide association studies (GWAS)
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on patients with NAFLD have shown that the mutation in
the vitamin D-binding protein gene (as the main vector of
vitamin D) is one of the four major polymorphisms associ-
ated with the risk of NAFLD (32). It has been shown that VDR
gene expression has an inverse relationship with the inten-
sity of NAFLD (33). On the other hand, it has been shown
that vitamin D levels have a positive and significant corre-
lation with the level of adiponectin, independent of BMI
(34). Adiponectin as an anti-inflammatory factor has an in-
verse relationship with NAFLD severity (35).
Our proposed model for the variables affecting the de-
velopment of NAFLD suggests that age, fasting insulin level
and vitamin D status are the strongest factors to predict in-
cidence of NAFLD. In this regard, using the minimum num-
ber of variables, we could predict the risk of NAFLD. The
area under the ROC curve for this model obtained 0.96 (95%
CI: 0.95 - 0.97). Accordingly, we could predict the risk of
NAFLD using fewer variables used in relevant studies. Lin
(36) announced that BMI, hemoglobin, fasting glucose and
triglyceride are the major variables to predict the risk of
NAFLD. However, in another study, BMI, WHR, triglyceride,
glucose, systolic blood pressure and ALT were reported as
the major influential factors in the used model (37). It
should be noted that compared to other relevant studies,
in our study, no anthropometric variables were entered
into the main model. This suggests that metabolic vari-
ables, including fasting insulin level possibly play a signifi-
cant role in enhancing the susceptibility to NAFLD. Anthro-
pometric variables, such as the waist size or BMI may exert
their effect through altering the level of metabolic factors,
including fasting insulin level (38, 39). Analysis of media-
tor variables are needed to confirm this finding (26).
According to our results, the cutoff point of vitamin D
level to increase the risk of NAFLD was 18.25 and 21.5 nmol/L
for women and men, respectively. Using the Youden’s in-
dex, which is calculated as the maximum sum of sensitiv-
ity and characteristics, the area under the curve for the cut-
off point obtained 0.865 and 0.858 for women and men, re-
spectively.
In many studies, the level of vitamin D has been com-
pared in patient and healthy individuals. In a meta-
analysis, Eliades et al. (14) investigated the level of vitamin
D in patients with NAFLD and concluded that those with
NAFLD had 0.36 ng/mL (95% CI: 0.32 - 0.40) lower serum vi-
tamin D level compared to the healthy subjects and also
they were 1.26 times more likely to suffer from vitamin
D deficiency (OR: 1.26, 95% CI: 1.17 - 1.35). By converting
to nmol/L, the difference in vitamin D level between two
groups obtained 1 nmol/L. However, the mean difference
between the two groups in our study was about 12 nmol/L.
This study faced some limitations. This research was a
cross-sectional study, which limited us to draw a causative
conclusion. Nevertheless, the studied population was
larger than most of other studies. One of the strengths of
our study is using volunteer healthy people who had not a
history of NAFLD, so as a population-based study, its results
can be generalized to the community. Our results showed
that an appropriate level of vitamin D can prevent the de-
velopment of NAFLD. Moreover, the samples were selected
by random sampling from those who referred to the med-
ical center following a recall through a year. Although it
minimized the possibility of selection bias, however sam-
pling in different seasons was another limitation of this
study. Using FibroScan device as a verified method to study
NAFLD (18, 40), confirming the results by a gastroenterol-
ogist using FibroScan device as well as the large number
of factors affecting NAFLD can enhance the reliability of
our research. However, conducting a longitudinal study at
multicenter level is suggested to obtain more accurate re-
sults.
5.1. Conclusions
The results of various studies and also our findings in-
dicate a significant relationship between vitamin D levels
and the risk of NAFLD. Particularly, our study suggests that
the values less than 18 nmol/L for women and 21 nmol/L
for men can increase the risk of NAFLD. Accordingly, the
level of 25 nmol/L can be introduced as the threshold for
preventing NAFLD in the community. In conclusion, it is
important to maintain the appropriate serum level of vi-
tamin D in preventing NAFLD that can be provided by con-
suming a vitamin D-rich food basket or by more exposure
to sunlight.
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